Last updated 4 days ago

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

999 patients around the world

Available in Puerto Rico, Argentina, United States

Amgen

999Patients around the world

This study is for people with

Diabetes

Diabetes mellitus type 2

Obesity

Requirements for the patient

To 99 Years

All Gender

Medical requirements

: Age ≥ 18 years.
Body mass index ≥ 27 kg/m².
History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.
Diagnosis of T2DM.

: Type 1 diabetes mellitus.
Self-reported change in body weight > 5 kg within 90 days before screening.
Proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment.
Obesity induced by other endocrinologic disorders.
Family (first-degree relative[s]) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2.
History of chronic pancreatitis or history of acute pancreatitis within 180 days before screening.
History of unstable major depressive disorder (MDD) or other severe psychiatric disorder within 2 years before screening.
Lifetime history of suicide attempt.

StudyMARITIME-2

SponsorAmgen

Study typeInterventional

Conditions

Diabetes mellitus type 2Obesity

Requirements

To 99 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06858878